Y
ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Geriatrics · Age Ageing · 2026-08-03

In a dose-response meta-analysis of 13 observational studies (7,891,574 adults with overactive bladder), anticholinergic use was associated with higher dementia risk (HR 1.52), rising sharply over the first 3 years and peaking at ~874 cumulative defined daily doses (HR 1.63).

Meta-analysisn = 7,891,574
Kim et al. Nonlinear dose-response relationship between cumulative anticholinergic use and the risk of dementia in adults with overactive bladder: a systematic review and dose-response meta-analysis
Geriatrics · Age Ageing · 2026-08-03

Secondary analysis of SPRINTT (1506 older adults): a lifestyle intervention did not significantly reduce mobility disability in benzodiazepine users (HR 1.04) or non-users (HR 0.86); in those with SPPB 3–7, benefit was seen only in non-users (HR 0.80; interaction P=.035).

Secondary analysisn = 1,506
Levati et al. Does the use of benzodiazepine influence the effectiveness of lifestyle intervention? Secondary analysis from the Sarcopenia and Physical fRailty iN older people strategies (SPRINTT) trial
Geriatrics · Age Ageing · 2026-08-03

In 25 long-term care residents with severe dementia (19 completed both periods), THC/CBD oil did not reduce agitation (CMAI) versus placebo in a crossover trial. As-needed psychotropic use was lower on THC/CBD, a secondary outcome; no related serious adverse events.

RCTn = 25
Bianchi et al. A randomised, double-blind, placebo-controlled crossover trial on cannabinoid-based medication for behavioural disorders in old patients with severe dementia: the study results

Sign in to react

Enter your email and we send a one-time link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.